<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784030</url>
  </required_header>
  <id_info>
    <org_study_id>08-774</org_study_id>
    <nct_id>NCT00784030</nct_id>
  </id_info>
  <brief_title>High Water Intake to Slow Progression of Polycystic Kidney Disease</brief_title>
  <official_title>The Effect of Water Loading on Urinary Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic kidney disease (PKD) is a genetic disease that occurs in 1 in 500 individuals and
      leads to kidney failure in half of all affected. Currently, no treatments exist for PKD.
      PKD-affected kidney cells divide and multiply inappropriately, and form fluid-filled sacs
      called cysts. Kidney cysts continue to grow throughout life, destroying normal kidney
      tissue, leading to kidney failure. Based on evidence from basic science research it is
      believed that drinking high amounts of water can slow the abnormal cysts growth. This study
      aims to look at changes in urine composition with high water intake in PKD-affected persons
      compared to healthy individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in Urine cAMP Concentration and Urine Osmolality (UOsm)</measure>
    <time_frame>pre- and post-water loading (2 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Kidney, Polycystic, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>Polycystic Kidney Disease Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who present with polycystic kidney disease (PKD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.</description>
    <arm_group_label>Polycystic Kidney Disease Patients</arm_group_label>
    <arm_group_label>Healthy Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Autosomal Dominant Polycystic Kidney Disease by history,
             ultrasound, CT or MRI

          -  Healthy subjects without a diagnosis of Polycystic Kidney Disease by history,
             ultrasound, CT or MRI

          -  Ages between 18 and 65

          -  Healthy subjects (without Polycystic Kidney Disease) must have an estimated
             glomerular filtration rate (eGFR by the MDRD equation) &gt; 60 ml/min/1.73 m2 with no
             history of kidney disease

        Exclusion Criteria:

          -  Women who are pregnant or nursing

          -  Active dependency on drugs or alcohol

          -  Diagnosis of syndrome of inappropriate antidiuresis

          -  Currently taking a vasopressin agonist or antagonist

          -  Blood sodium level less than &lt; 135 mEq/L

          -  For healthy participants, estimated glomerular filtration rate (level of kidney
             function) less than &lt; 60 ml/min/1.73 m2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Barash, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>October 31, 2008</firstreceived_date>
  <firstreceived_results_date>April 25, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Polycystic Kidney Disease</keyword>
  <keyword>Water Loading</keyword>
  <keyword>Biomarkers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Polycystic Kidney Disease (PKD) Patients</title>
          <description>Patients who present with polycystic kidney disease (PKD)</description>
        </group>
        <group group_id="P2">
          <title>Healthy Patients</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Polycystic Kidney Disease (PKD) Patients</title>
        </group>
        <group group_id="B2">
          <title>Healthy Patients</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine cAMP Concentration and Urine Osmolality (UOsm)</title>
        <description>Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours</description>
        <time_frame>pre- and post-water loading (2 hours)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of participants was deemed to be adequate for the purposes of this pilot study</population>
        <group_list>
          <group group_id="O1">
            <title>Polycystic Kidney Disease Patients</title>
            <description>Patients with Autosomal Dominant Polycystic Kidney Disease</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>Healthy Controls</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Urine cAMP Concentration and Urine Osmolality (UOsm)</title>
            <description>Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours</description>
            <units>fold change in cAMP/UOsm (umol/UOsm)</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.6" spread="0.2"/>
                  <measurement group_id="O2" value="-2.0" spread="0.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Polycystic Kidney Disease Patients</title>
          <description>Patients with Autosomal Dominant Polycystic Kidney Disease</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>Healthy Controls</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a very small study, so larger numbers are needed. Urine cAMP measurement as a surrogate of response to water treatment needs further validation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Irina Barash</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212.263.5851</phone>
      <email>irina.barash@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
